AstraZeneca COVID-19 vaccine study put on hold after adverse reaction
Sep. 8, 2020
"Standard review process triggered a pause to vaccination to allow review of safety data," says an AstraZeneca (NYSE:AZN) spokesperson after a Phase 3 study of its COVID-19 vaccine (developed with University of Oxford) has been put on hold across the U.S. after a suspected serious adverse reaction on a U.K. participant